Research ExplorerPublicationsRepurposing Zileuton as a Depression Drug Using an AI and In...

Repurposing Zileuton as a Depression Drug Using an AI and In Vitro Approach

Standard

Repurposing Zileuton as a Depression Drug Using an AI and In Vitro Approach. / Kubick, Norwin; Pajares, Marta; Enache, Ioana; Manda, Gina; Mickael, Michel-Edwar.

In: MOLECULES, Vol. 25, No. 9, 05.05.2020.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kubick, N, Pajares, M, Enache, I, Manda, G & Mickael, M-E 2020, 'Repurposing Zileuton as a Depression Drug Using an AI and In Vitro Approach', MOLECULES, vol. 25, no. 9. https://doi.org/10.3390/molecules25092155

APA

Kubick, N., Pajares, M., Enache, I., Manda, G., & Mickael, M-E. (2020). Repurposing Zileuton as a Depression Drug Using an AI and In Vitro Approach. MOLECULES, 25(9). https://doi.org/10.3390/molecules25092155

Vancouver

Kubick N, Pajares M, Enache I, Manda G, Mickael M-E. Repurposing Zileuton as a Depression Drug Using an AI and In Vitro Approach. MOLECULES. 2020 May 5;25(9). https://doi.org/10.3390/molecules25092155

Bibtex

@article{29fbf6393be343a393249453484216f5,
title = "Repurposing Zileuton as a Depression Drug Using an AI and In Vitro Approach",
abstract = "Repurposing drugs to target M1 macrophages inflammatory response in depression constitutes a bright alternative for commonly used antidepressants. Depression is a significant type of mood disorder, where patients suffer from pathological disturbances associated with a proinflammatory M1 macrophage phenotype. Presently, the most commonly used antidepressants such as Zoloft and Citalopram can reduce inflammation, but suffer from dangerous side effects without offering specificity toward macrophages. We employed a new strategy for drug repurposing based on the integration of RNA-seq analysis and text mining using deep neural networks. Our system employs a Google semantic AI universal encoder to compute sentences embedding. Sentences similarity is calculated using a sorting function to identify drug compounds. Then sentence relevance is computed using a custom-built convolution differential network. Our system highlighted the NRF2 pathway as a critical drug target to reprogram M1 macrophage response toward an anti-inflammatory profile (M2). Using our approach, we were also able to predict that lipoxygenase inhibitor drug zileuton could modulate NRF2 pathway in vitro. Taken together, our results indicate that reorienting zileuton usage to modulate M1 macrophages could be a novel and safer therapeutic option for treating depression.",
author = "Norwin Kubick and Marta Pajares and Ioana Enache and Gina Manda and Michel-Edwar Mickael",
year = "2020",
month = may,
day = "5",
doi = "10.3390/molecules25092155",
language = "English",
volume = "25",
journal = "MOLECULES",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",

}

RIS

TY - JOUR

T1 - Repurposing Zileuton as a Depression Drug Using an AI and In Vitro Approach

AU - Kubick, Norwin

AU - Pajares, Marta

AU - Enache, Ioana

AU - Manda, Gina

AU - Mickael, Michel-Edwar

PY - 2020/5/5

Y1 - 2020/5/5

N2 - Repurposing drugs to target M1 macrophages inflammatory response in depression constitutes a bright alternative for commonly used antidepressants. Depression is a significant type of mood disorder, where patients suffer from pathological disturbances associated with a proinflammatory M1 macrophage phenotype. Presently, the most commonly used antidepressants such as Zoloft and Citalopram can reduce inflammation, but suffer from dangerous side effects without offering specificity toward macrophages. We employed a new strategy for drug repurposing based on the integration of RNA-seq analysis and text mining using deep neural networks. Our system employs a Google semantic AI universal encoder to compute sentences embedding. Sentences similarity is calculated using a sorting function to identify drug compounds. Then sentence relevance is computed using a custom-built convolution differential network. Our system highlighted the NRF2 pathway as a critical drug target to reprogram M1 macrophage response toward an anti-inflammatory profile (M2). Using our approach, we were also able to predict that lipoxygenase inhibitor drug zileuton could modulate NRF2 pathway in vitro. Taken together, our results indicate that reorienting zileuton usage to modulate M1 macrophages could be a novel and safer therapeutic option for treating depression.

AB - Repurposing drugs to target M1 macrophages inflammatory response in depression constitutes a bright alternative for commonly used antidepressants. Depression is a significant type of mood disorder, where patients suffer from pathological disturbances associated with a proinflammatory M1 macrophage phenotype. Presently, the most commonly used antidepressants such as Zoloft and Citalopram can reduce inflammation, but suffer from dangerous side effects without offering specificity toward macrophages. We employed a new strategy for drug repurposing based on the integration of RNA-seq analysis and text mining using deep neural networks. Our system employs a Google semantic AI universal encoder to compute sentences embedding. Sentences similarity is calculated using a sorting function to identify drug compounds. Then sentence relevance is computed using a custom-built convolution differential network. Our system highlighted the NRF2 pathway as a critical drug target to reprogram M1 macrophage response toward an anti-inflammatory profile (M2). Using our approach, we were also able to predict that lipoxygenase inhibitor drug zileuton could modulate NRF2 pathway in vitro. Taken together, our results indicate that reorienting zileuton usage to modulate M1 macrophages could be a novel and safer therapeutic option for treating depression.

U2 - 10.3390/molecules25092155

DO - 10.3390/molecules25092155

M3 - SCORING: Journal article

C2 - 32380663

VL - 25

JO - MOLECULES

JF - MOLECULES

SN - 1420-3049

IS - 9

ER -